Clinic Roundup

 Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said it completed a study testing radiopharmaceutical NAV4694 as a biomarker for visual detection and quantification of cerebral beta-amyloid in diagnosing Alzheimer's disease.